American Bio Medica Corporation (ABMC)

$0.019

-0.00 (-5.47%)
Rating:
Recommendation:
-
Symbol ABMC
Price $0.019
Beta -0.947
Volume Avg. 0.01M
Market Cap 0.914M
Shares () -
52 Week Range 0.019-0.1
1y Target Est -
DCF Unlevered ABMC DCF ->
DCF Levered ABMC LDCF ->
ROE 25.59% Buy
ROA -18.27% Sell
Operating Margin -
Debt / Equity -219.65% Sell
P/E -
P/B -0.69
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Ms. Melissa A. Waterhouse
Healthcare
Diagnostics & Research
Other OTC

American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to non-affiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.